Desensitization and Induction Immunosuppressive Therapy in Highly HLA-Sensitized Patients Receiving Cadaveric Renal Allograft) by Rufino Hernández, Juana Margarita et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Desensitization and Induction 
Immunosuppressive Therapy 
in Highly HLA-Sensitized Patients 
Receiving Cadaveric Renal Allograft 
Juana Margarita Rufino Hernández1, José Manuel González-Posada 
Delgado1 and Domingo Hernández Marrero2 
1Nephrology Section. Hospital Universitario de Canarias, Tenerife 
2Nephrology Section. Hospital Universitario Carlos Haya,  Málaga 
Spain 
1. Introduction 
Approximately 15-20% of patients on the waiting list for cadaveric renal transplant are highly 
HLA-sensitized. It is well known that the presence of alloantibodies against human class I (A, 
B, C) and class II (DR, DQ) HLA antigens in transplant recipients waiting for a renal transplant 
has a significant increase in acute and chronic rejection rates and a poor graft outcome. There 
are interesting options for minimizing these immunological problems such as national paired 
kidney exchange program or acceptable mismatch program similar to the one developed by 
Eurotransplant program. However, despite these efforts, these patients can wait up to 5 years 
for a kidney graft and just get it finally only 30% of them. It is therefore vital to develop 
strategies to reduce waiting time and decrease the risk of transplant rejection, through the 
elimination or reduction of circulating lymphocytotoxic antibodies. 
There have been several retrospective and prospective studies that have used 
immunoabsorption or plasmapheresis together with immunosuppressants and intravenous 
immune globulins with highly variable success rates that, while not providing a high level 
of evidence, constitutes a promising therapeutic alternative for these patients.  
In addition, the use of rituximab in living donor transplantation ABO incompatible, 
hypersensitive patients with positive crossmatch, acute rejection resistant to standard 
treatments and pretransplant desensitization are running with very interesting results. 
Moreover, newer approaches for treating acute humoral rejection such as the proteosome 
inhibitor (bortezomib) or eculizumab (an anticomplement monoclonal antibody), are 
emerging as successful therapeutic options (Gloor J Stegall, 2010).  
Long-term follow- up of these patients and the application on a wider scale of these 
treatments, will provide the definitive answers about their real efficacy (Nocera, 2009). 
Nevertheless, acute antibody-mediated rejection (AMR), occurring in 20-50% of patients, 
and subclinical AMR even in the absence of allograft dysfunction, may decrease allograft 
survival by chronic histological abnormalities. 
The aim of this chapter is to review the current data about approach therapy in highly HLA-
sensitized patients receiving deceased renal allograft. 
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2. Definition of highly HLA-sensitized patients 
Patients with PRA (panel reactive antibodies) permanently > 75%, plus HLA-polyspecific 
reactivity by complement dependent cytotoxicity (CDC) or flow cytometry and multiple 
previous positive crossmatch, should be considered highly HLA-sensitized patients. HLA 
antibodies, are present in hyperimmunized patients as a result of pregnancies, blood 
transfusions and previous failed grafts, and make up an important barrier to renal 
transplantation. 
There are different assays that can be used to determine the PRA, but it is necessary to 
ensure efficiency and reliability of these tests, so that that each laboratory must continuously 
monitor its processes and results (Ercilla MG, 2010). Monitoring is guaranteed by the 
accreditation of processes as well as quality control of results, evaluated by external 
organisations of experts on histocompatibility (for example, the accreditation programme of 
the European Federation for Immunogenetics and the American Society for 
Histocompatibility and Immunogenetics). 
2.1 The complement dependent cytotoxicity (CDC) assay 
A complement-mediated cytotoxicity reaction occurs when an IgM or IgG reacts against an 
antigen present on the cell surface of specific tissues. After this reaction, the complement 
system activation leads to cell membrane damage and, secondarily, cell lysis. In addition, 
the cells covered by the antibody (opsonized) are susceptible to be ingested by the 
monocyte-macrophage system, as it reduces the ionic charge of the cell surface directly 
through immune adherence or by binding to C3.  
The complement dependent cytotoxicity (CDC) assay estimates PRA by adding potential 
recipient serum to microtiter plates that contain a pool of lymphocytes with defined HLA 
antigens. Rabbit complement is added and the plates are viewed after addition of a vital 
stain. The PRA can then be determined based upon the number of cytotoxic reactions that 
are observed. The classic assay CDC crossmatch has a high positive predictive value for 
graft loss in the first 48 hours if positive, which therefore contraindicates transplantation. 
Alloantibody testing should be performed every three months in all candidate patients for 
renal transplantation and 15 days after each sensitising event (transfusion, graft loss and 
pregnancy). This sequential study helps to reveal antibodies that may have been identified 
in the past but that may not have been detected at the time of transplantation. If the 
crossmatch is positive by CDC, the process is repeated with the addition of Dithiothreitol 
(DTT). This step reduces the disulfide bonds present when the antibody is IgM.  
A test that is CDC positive/DTT negative (presence of an IgM antibody only) should not 
preclude transplantation: in this case, the determination of solid-phase anti-HLA 
alloantibody screening (by immunoabsorption ELISA or flow cytometry, Luminex) is 
negative in serum that was CDC-PRA positive. By comparison, the presence of a CDC 
positive/DTT positive test is an indication of IgG anti-donor antibody and is a 
contraindication to transplantation without the use of a desensitization procedure, 
especially if a donor specific antibody has been defined. (Klein, 2010; Ercilla MG, 2010) 
2.2 The enzyme-linked immunoabsorption (ELISA) 
This assay uses microtest trays containing known HLA antigens to which potential recipient 
serum is added. This test is faster than the CDC assay and the HLA antigens used for 
screening can be adjusted as necessary to reflect the presumed potential donor pool. As in 
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the cytotoxicity technique, the mix of antigens should be representative of the general 
population. In case of anti-HLA antibodies, a colorimetric reaction enzyme occurs. This 
reaction is quantified by spectrophotometer.  
By ELISA assay, we detect all anti-HLA antibodies, including complement fixing and non-
fixers. Once it has detected the presence of anti-HLA antibodies (class I or II), specificity 
against which these antibodies are directed can also be determined by a high definition 
ELISA plates or unique antigens with the same methodology.  Solid-phase anti-HLA 
alloantibody screening is useful when autoantibodies are suspected and there is a need to 
rule out them in a patient with positive CDC-PRA. This indicates presence or absence of 
type IgG anti-HLA antibodies against anti-HLA-I and anti-HLA-II and, in some kits, anti-
MICA. By using purified HLA antigens, non-anti-HLA antibodies are not identified. If anti-
HLA antibodies are not revealed by cytotoxicity but are detected by solid phase, it is highly 
recommended that more sensitive crossmatch techniques should be used, such as flow 
cytometry or virtual crossmatch (VCM) in order to better define the risk for these patients. 
(Klein, 2010; Ercilla MG, 2010). 
2.3 Flow cytometry. Single-antigen bead flow cytometry (SAB-FC) 
Flow cytometry measures the fluorescence after patient serum has been added to a defined 
set of HLA antigen flow beads. A positive test is determined by the mean channel shift in 
intensity, that is, mean intensity of fluorescence (MFI).  This assay allows to identify specific 
HLA antigens to which the patients are sensitized and constitutes what we know as "virtual 
lymphocyte crosssmatch (VCM)." VCM is indicated in patients who are candidates for 
retransplantation, women who have previously been multiple pregnant and those with 
positive results in the solid-phase screening but negative for CDC as well as also is 
recommended for all living-donor transplants.  
In the event that the only positive result is that of the positive VCM, this will indicate a 55% 
probability of an antibody-mediated rejection episode in the first year versus a 5% 
probability in the case of a negative VCM and the graft survival at one year is slightly lower. 
However, a positive VCM, by itself, does not imply that a transplant is necessarily 
contraindicated, but a careful monitoring and immunosuppression aimed to controlling 
alloantibody production are needed for a thorough treatment.  
A positive B-cell negative T-cell crossmatch usually occurs in presence of anti-HLA-II 
antibodies, presence of low-titre anti-HLA-I antibodies detectable only in B lymphocytes 
and presence of specific B lymphocytes autoantibodies. In these cases, the decision for 
transplantation must be individualised. In others words, T cell negative/B cell positive 
reactions may be secondary to either class I or class II antibodies, while a T cell positive/B 
cell negative reaction most likely results from a non-HLA antibody, as class I antigen is 
expressed on both T and B cells. For living donor recipients, perform a monocyte crossmatch 
should be useful as may help to detect anti-endothelial antibodies. 
Clearly identifying the reactivity of antibodies with the donor (DSAs) is logistically difficult 
because it requires donor cells which may be stored frozen in liquid nitrogen, or determined 
of the living donor who has to be present for each determination. Therefore, is in these cases, 
when the crossmatch cannot be performed due to lack of donor cells, where this assay plays 
an important role as it allows identify specific HLA antigens to which the patient is 
sensitized (virtual lymphocyte crosssmatch).   
Singh N et al showed the impact that produces pre-Tx DSAs detected by SAB-FC on early 
clinical outcomes. They tested pre-Tx sera from all consecutive deceased-donor kidney 
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transplants performed between January 2005 and July 2006 (n=237), 66% had a high-
immunologic risk. MFI more than or equal to 100 for class I and more than or equal to 200 
for class II were the lowest DSA thresholds associated with inferior antibody-mediated 
rejection-free graft survival (Singh N et al., as cited in Ercilla MG, 2010). The presence of 
class I-anti-HLA antibodies post-transplant precedes, even by years, the development of 
glomerulopathy. In addition, the presence of anti-class II antibodies is strongly associated 
with chronic rejection in living-donor kidney recipients, but it appears that the worst 
prognosis is associated with the simultaneous detection of anti-HLA-I and anti-HLA-II 
antibodies.  
There is evidence that it is possible to reduce pre-existing circulating alloantibodies in some 
patients to levels where the antibodies are unable to trigger hyperacute rejections. This does 
not imply that there are no B lymphocytes with the capacity to restart alloantibody 
production, but the short-term survival of grafts transplanted in some centres under these 
conditions is acceptable. (Klein, 2010; Ercilla MG, 2010).  
Compared with the cell-based method, the fluorometric bead system is not as susceptible to 
drug interference, such as antithymocyte globulin, intravenously administered 
immunoglobulin (IVIG), and rituximab. IVIG may interfere with the bead assay for a few 
days after administration. Nonetheless, these new techniques allow for greater identification 
of HLA antibody specificities and a more accurate interpretation of cross-match results. 
Patients with high DSA and donor-specific cross matches SFI units are considered at high 
risk for AMR and warranted more frequent antibody-level monitoring posttransplantation, 
may need desensitization treatments, or plan biopsies, in order to reduce DSA levels or 
detect early AMR respectively; sometimes, increase in DSA imply retreatment as can result 
in reduction in DSA, levels to ≤105 SFI units is usually associated with a low risk of AMR.  
3. Immunosuppressive therapy in high immunologic risk patients receiving 
cadaveric renal allograft 
3.1 Immunosuppressive agents 
3.1.1 Anti-lymphocyte antibodies 
Thymoglobulin is a polyclonal immunosuppressive agent that is generated in rabbits, 
containing antibodies to a wide variety of human T-cell surface antigens, including the 
major histocompatibility complex (MHC) antigens. These antibodies have the ability to 
block a number of adhesion molecules, cytokines, chemokines, among others. Anti-
lymphocyte antibodies have long been an integral part of induction regimens and, nowdays, 
continue to be used in the management of patients at risk of early rejection. They are used in 
combination with steroids, mycophenolate and calcineurin inhibitors or, less frequently, 
proliferation signal inhibitors and are treatment of choice for acute graft rejection grade II 
and III of Banff or unresponsive to steroid boluses. Among the available polyclonal globulin, 
thymoglobulin, has shown a great efficacy and typically requires between 7 and 10 doses.  
The reaction of these globulins with some lymphocyte antigens can trigger activation of 
these cells to release cytokines, which may present with chills, fever and systemic 
symptoms, mainly with the first dose. Steroids, antihistamines and antipyretics intravenous 
infusion may prevent these early reactions; polyclonal antibodies will be made through a 
central venous catheter in at least 6 hours.  
Side effects in the medium and long term are related to its immunosuppressive effect. 
Polyclonal antibodies can increase the risk of infection (herpes simplex virus, varicella-
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zoster virus, cytomegalovirus or Epstein-Barr virus) and patients may benefit from 
prophylactic antiviral strategies. Other opportunistic infections may be due to pneumocystis 
jiroveci and aspergillus, but are related to immunosuppression accumulated by the patient 
rather than the administration of polyclonal antibodies. Treatment with antilymphocyte 
globulin and a serum test for Epstein-Barr virus receptor are associated with the risk of 
lymphoproliferative disorders in renal transplant population. (Gaber ,AO et al., 2010; 
Oppenheimer, F et al., 2010) .  
Currently almost 70% of renal transplant patients in the United States receive antibody 
induction, either antithymocyte globulin (Thymoglobulin) or inhibitors of IL-2. Brennan, D 
et al. (Brennan, C et al., 2006) compared the efficacy and safety of randomized use of 
basiliximab versus thymoglobulin in patients at high risk of rejection (retransplantation, 
PRA greater than 20% black, one or more HLA incompatibilities) or delayed graft function 
who received a cadaveric renal transplantation. After 12 months of follow-up, incidence of 
biopsy proven acute rejection was 15.6% for Thymoglobulin, and 25.2% for basiliximab (p = 
0.02) and the antibody-treated acute rejection was lower in patients with thymoglobulin 
(1.4% vs 8.0%, p = 0,005). The overall rate of adverse events was 99.3% to 98.5%, was similar 
between boths induction treatment. The overall incidence of infection was 85.8% to 75.2% 
with thymoglobulin and basiliximab (p = 0.03). This difference appears to be attributable to 
a higher frequency of urinary tract infection and no CMV viral infections. CMV infection 
was lower with Thymoglobulin (7.8% vs 17.5%, p = 0.02), probably due that a prophylactic 
antibiotics were used less in patients with thymoglobulin (18.9% vs 30.9%, p = 0.03).   
3.1.2 Alemtuzumab 
Alemtuzumab is a humanized IgG1 kappa monoclonal antibody, genetically engineered, 
specific for a surface glycoprotein of lymphocytes, 21-28 kD (CD52) present on T and B 
lymphocytes, natural killer cells and to a lesser extent on monocytes and macrophages. It is 
indicated for the treatment of patients with chronic lymphocytic leukemia who have been 
treated with alkylating agents and who have not achieved a complete or partial response. 
Alemtuzumab causes lysis of lymphocytes by binding to CD52, the antibody mediates lysis 
of lymphocytes by complement fixation and cell-mediated cytotoxicity, antibody-
dependent. The antigen has been detected in a small percentage (<5%) of granulocytes, but 
not detected in erythrocytes or platelets. Alemtuzumab does not appear to damage the 
hematopoietic stem cells or progenitor cells. Side effects include first-dose reactions, less 
severe than those due to OKT3, as well as anemia, leukopenia and pancytopenia. Further 
long-term controlled studies are needed to establish the potential benefit in terms of efficacy 
and safety after kidney transplantation. 
3.1.3 OKT3 
OKT3 is a murine monoclonal antibody against the T3 antigen of human lymphocytes which 
acts as an immunosuppressant by blocking a molecule (CD3) located in the membrane of 
human T cells. This molecule appears to be associated with the structure of antigen 
recognition of T cells. It is indicated to treat acute rejection reaction in renal transplant 
patients. It must be only used in intravenous form and the dose of other 
immunosuppressive agents used concomitantly with OKT3 should be decreased to minimal 
levels and restarted about three days before the end of treatment with OKT3. It produces a 
rapid and concomitant decrease in the number of circulating T cells (CD3, CD4 and CD8) 
after the administration. After discontinuation of treatment, CD3 cells reappear rapidly and 
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reach pretreatment levels within a week. OKT3 should not be used in patients with 
hypersensitivity to this or any other product of murine origin and in patients with fluid 
overload or with a history of seizures or a predisposition to allergies. After the first dose of 
OKT3 patients may experience fever, chills, malaise, encephalopathy, aseptic meningitis, 
dysnea and with minor frequency, fatal severe pulmonary edema. The most common 
infections were cytomegalovirus (19%) and herpes simplex (27%). To summarize, OKT3 was 
the first monoclonal antibody against CD3 used but adverse effect profile makes little used 
today. 
3.1.4 Intravenous immunoglobulin (IVIG) 
Intravenous immunoglobulin (IVIG) products: are derived from pooled human plasma and 
have been used for the treatment of primary immunodeficiency disorders, autoimmune and 
inflammatory disorders and recently in the treatment of sensitized patients. Mechanism of 
action: neutralization of circulating antibodies through idiotype-idiotype interactions to 
inhibit the binding of Ac antiHLA to their target cells in a dose-dependent form; inhibition 
of secretion of cytokines and other soluble mediators; stimulation of cytokine receptor 
antagonists; interaction with antigen-presenting cells by blocking T cell activation through 
the Fc receptor; inhibition of binding of the fractions of complement to target cells because 
they have a high affinity for activated complement components C3b and C4b resulting in 
decreased formation of the potent anaphylatoxin C5a and the C5b-C9 membrane attack 
complex, inhibition of proliferation of T and B cells and "down regulation" of the synthesis 
of antibodies and others.  
Plasmapheresis, in combination with intravenous immunoglobulin, produces durable, 
donor-specific antibody suppression as effect of plasmapheresis is short-lived, and a 
rebound occurs usually when plasmapheresis is discontinued and half-life of IVIg is about 3 
weeks; therefore, in most protocols its administration is repeated every 4 weeks. In adition, 
IVIG are useful in the treatment and prevention of posttransplant infectious complications 
including cytomegalovirus, parvovirus B19 and polyoma BK virus. Adverse effects are 
minor: headaches, fever, fatigue, myalgia, hypotension, sweating, dizziness, chills, chest 
tightness, wheezing. They all probably are secondary to increased levels of inflammatory 
cytokines and vasoactive substances and with high velocity perfusion. Anaphylactic 
reaction and shock can occur in patients with total or partial deficiency of IgA. In these 
cases, epinephrine, and diazepam for muscle spasms are indicated. Another adverse effect is 
renal dysfunction, because of the content of sucrose or sorbitol which can cause osmotic 
nephrosis in the proximal tubule. This can be avoided by reducing the osmolarity of 
immunoglobulin products containing sucrose, using restorative with sterile water instead of 
saline and lowers the concentration of Igs and sucrose to <9%. Other life-threatening side 
effects are thrombotic events. Very slow infusion using IVIG at a concentration of 5%, with 
low or no sodium content and low osmolarity, and using molecular weight heparin reduces 
the incidence. 
3.1.5 Rituximab 
It is a chimeric antibody mouse / human directed against the CD20 antigen on B 
lymphocytes (expressed in mature B lymphocytes and prelinfocito B). Directly inhibits B cell 
proliferation, induces apoptosis and reduces the production of antibodies. It has been used 
for the treatment of non-Hodgkin's lymphoma B cells, rheumatoid arthritis, autoimmune 
diseases such lupus, idiopatic thrombopenic purpure, cryoglobulinemia and organ 
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transplantation. It produces rapid reduction of B cells with subsequent recovery at 12 
months. Recent clinical data suggest that the beneficial effects of rituximab may be due to 
depriving T cells of antigen-presenting cell activity provided by antigen-specific B cells, thus 
altering effect or functions and inducing a regulatory profile. These data suggest that the 
beneficial effects of rituximab on autoimmune disease are more likely related to 
modification of dysfunctional cellular immunity rather than simply a reduction in antibody. 
A single dose of 375 mg/m2 in renal transplantation produces depletion of CD19 and CD20 
cells for long periods in peripheral blood and tissue level.  
Rituximab can be administered in a peripheral vein and, although rare, can cause 
anaphylactic reactions, which suggests his administration under close monitoring. The use 
of rituximab, which is directed against the CD20 antigen, would seem to be a logical 
strategy, since reduction or elimination of B cells that express CD20 and make anti-HLA 
antibodies, should have a beneficial effect. However, there are problems with this concept. 
First, anti-CD20 activity has no effect on plasma cells, which are the primary source of acute 
antibody production and second, rituximab has no immediate effect on circulating antibody 
levels. These problems might limit the benefit of rituximab if were used as the sole 
treatment, however, it appears that the use of rituximab in combination with other 
treatments, e.g., plasmapheresis which eliminates circulating antibodies, and intravenous 
immune globulin, that acts neutralizing circulating antibodies through idiotype-idiotype 
interactions to inhibit the binding of Ac antiHLA, or both, might constitute an improved 
approach for the management of allosensitization.  
There are concerns regarding the use of rituximab, because it has been reported to induce 
reactivation of polyomavirus JC virus, resulting in progressive multifocal 
leukoencephalopathy. Optimal treatment of AMR probably requires a combination of 
rituximab with PP and low-dose IVIG or with high-dose IVIG (1–2 gm/kg) due to the 
inability of rituximab to deplete CD20-negative plasma cells that continue to produce DSA 
and mediate graft injury. 
3.1.6 Calcineurin-inhibitors 
Cyclosporine A binds to an intracellular receptor (cyclophilin) and form an active complex 
that binds and inhibits the phosphatase activity of calcineurin. Calcineurin participates in 
the transcriptional control of ribonucleic acid for the synthesis of cytokines (IL-2, IFN-Ǆ, IL-4 
and TNF-ǂ). Thus, inhibits the proliferation of T cells preventing clonal expansion of helper 
and cytotoxic T cells; suppressor T cells are not affected. 
Tacrolimus is a macrolide that forms a complex intracytoplasmic with a specific 
immunophilin (FKBP) capable of blocking the phosphatase activity of calcineurin, and 
thereby inhibit transcription of different genes (IL-2 and others). It inhibits the activation 
and proliferation of T cells and the synthesis of cytotoxic T lymphocytes. It also slows the 
growth and differentiation of B cells by interfering with the expression of IL-4 receptor and 
IL-5 synthesis. Unlike cyclosporin, tacrolimus does not interact with the receptor of 
transforming growth factor beta (TGF-ǃ) type 2, which would provide more efficacy in 
preventing chronic graft rejection. Tacrolimus is used to prevent acute graft rejection and for 
treatment of corticosteroids-resistant acute rejection. It is administered in combination with 
steroids and derivatives of mycophenolic acid and mTOR inhibitors.  
Adverse effects with greater clinical significance are nephrotoxicity, similar to that produced 
by cyclosporine A, carbohydrate intolerance and diabetes mellitus, neurological disorders: 
tremor, headache, dizziness, and severe neurological (seizures, encephalopathy, etc.) and 
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also increased susceptibility to development of infections and malignancies. (Oppenheimer, 
F et al., 2010). 
3.1.7 Derivatives of mycophenolic acid, mycophenolate mofetil or enteric-coated 
mycophenolic acid 
Mycophenolate is an ethyl ester of mycophenolic acid that selectively inhibits de novo 
synthesis of purines, the proliferation of T and B lymphocytes, the expression of adhesion 
molecules and proliferation of smooth muscle cells of the vascular wall. The enteric-coated 
mycophenolic acid sodium salt is designed to try to improve gastrointestinal tolerance. The 
efficacy and safety of both drugs are similar. Its main indication is the prevention of acute 
graft rejection and may play an important role in preventing chronic rejection. Commonly 
used with cyclosporine A or tacrolimus to prevent acute graft rejection and have also been 
proposed for the treatment of corticosteroid-resistant acute rejection or refractory to 
treatment.  May appear blood disorders (anemia, leukopenia and thrombocytopenia), which 
are not severe. Viral infections, especially citomegalolvirus are more frequent than when 
used in place of mTOR inhibitors. (Oppenheimer, F et al., 2010) 
3.1.8 mTOR inhibitors, sirolimus and everolimus 
Anti-mTOR drugs, sirolimus and everolimus are potent immunosuppressants with 
antiproliferative and anti-migratory capacity that act by blocking the intracellular signalling 
that regulates the growth and proliferation of T2 cells. mTOR inhibitors are macrolide acting 
in a late stage cell proliferation by inhibiting cytokine-specific signals. To act it requires form 
a complex with an immunophilin, but unlike the tacrolimus, do not inhibit calcineurin. 
Everolimus is a derivative of sirolimus with a shorter elimination half-life and greater oral 
bioavailability.  
In primary immunosuppression, associated with cyclosporine A, have a synergistic 
immunosuppressive effect, and the incidence of acute rejection varies between 10 and 20%. 
While competing for the same tacrolimus cyclophilin, the association of mTOR inhibitor- 
tacrolimus is, at least, as effective as tacrolimus, mycophenolic acid association. Its main 
advantage is a reduction in the appearance of de novo tumours and the absence of 
nephrotoxicity, although significant proteinuria has been reported, especially after late use 
in grafts with impaired function. In cases of nephrotoxicity may be useful in association 
with mycophenolate, after discontinuation of calcineurin. An additional advantage is the 
lower rate of cytomegalovirus infection. Its side effects are: hypercholesterolemia, 
hypertriglyceridemia and thrombocytopenia, which are related to the administered dose. 
These side effects may offset their benefits in the longer term in highly renal transplant 
considering that are patients with high immunological risk whose should remain on full-
dose triple therapy. 
3.1.9 Proteosome inhibitor (bortezomib) 
Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, 
induces plasma cell apoptosis. Its role in desensitization protocols and treatment of humoral 
rejection may offer promise results in transplant recipients. The pharmacokinetics of 
bortezomib can be characterized by rapid and wide distribution, a prolonged elimination 
half life, and hepatic cytochrome P-450 (CYP) isoenzyme metabolism. Side effects more 
frequent are a low-grade gastrointestinal side effect, mild to moderate anemia, neutropenia, 
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and thrombocytopenia, and primarily mild cases of peripheral neuropathy. Despite the mild 
decrease in PRA levels, bortezomib therapy led to more than 50% decrease in the levels of 
anti-HLA antibodies triggering C4d deposition on single antigen Luminex beads as 
measured in MFI with single-antigen bead flow cytometry. 
Results in desensitization of patients with this agent before transplantation are less 
consistent. Wahrmann et al. could not observe a significant decrease of circulating HLA 
antibodies in two highly sensitized dialysis patients who were treated with two cycles of 
bortezomib, indicating that this agent is not able to eliminate long-lived plasma cells. 
Furthermore, in vitro studies indicate that contact with alloantigen enhances the 
susceptibility of plasma cells to proteasome inhibition-mediated apoptosis, which might also 
serve as an explanation for the observed differences in the effectivity of bortezomib in the 
pre- and posttransplant phases. 
In the study by Walsh et al., two patients undergoing acute AMR with high DSA and 
positive C4d staining on biopsy two weeks after kidney transplantation were treated with a 
multiday regimen consisting of plasmapheresis, methylprednisolone and bortezomib along 
with a single dose of rituximab. By nearly 14 days after treatment, DSA levels had dropped 
significantly as well as repeat biopsy showed faint peritubular capillary C4d labeling and 
decreased glomerular C4d deposition.  
Trivedi et al. (Trivedi et al., 2009, 2010) reported thirteen living donor renal transplant 
patients treated with bortezomib one to two cycles and plasmapheresis to remove HLA 
antibodies posttransplant. All patients treated with bortezomib/plasmapheresis resulted in 
a primary DSA reduction of more than 50% measured by means of single antigen bead on 
Luminex. In 10 of 13 patients, complete DSA removal, below than 1000 mean fluorescent 
intensity occurred. At 1 year posttreatment, antibody intensity remains significantly 
depressed in the group as a whole, despite tetanus toxoid and measles IgG levels remained 
unchanged and above the level of protection. These data suggest that proteasome inhibitors 
plus plasmapheresis results in prolonged reduction of HLA antibodies while leaving 
protective immunity intact. Some patients had reappearance of anti-HLA antibodies despite 
initial effective reduction, and the authors suggested that certain patients may need more 
than one cycle of treatment to decrease DSA levels.  
3.1.10 Eculizumab (anti-C5, anticomplement monoclonal antibody) 
The monoclonal antibody eculizumab, which binds to complement factor C5 and prevents 
formation of the membrane attack complex C5b-9, is currently in clinical use for the 
treatment of paroxysmal nocturnal hemoglobinuria and being tested for the treatment of 
atypical hemolytic uremic syndrome. Its use combined with plasmapheresis or IVIg decrease 
C5b-C9 complex deposition in the kidney. It is very important to be immunized against 
meningitis (Neisseria meningitidis) to all patients two weeks before the administration of 
eculizumab as due to its mechanism of action, the use of this drug increases the patient's 
sensitivity to meningococcal infection.  
Eculizumab selectively inhibits the human complement protein C5, preventing its division 
into C5a and C5b, thus annulling the formation of C5b-9 terminal complement, which is 
behind the formation of transmembrane channels that cause cell lysis. The adverse reactions 
most frequently reported are headache, nasopharyngitis, nausea, pyrexia, myalgia, fatigue 
and herpes simplex, observed in at least 5 of every 100 patients. The most serious side effect 
was meningococcal septicemia.  
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Complement activation plays a critical role in mediating AMR after kidney transplantation. 
As eculizumab has the ability to inhibit C5b-C9 MAC and C5a generation, it should act as a 
strong accommodation promoter and prevent AMR. Fortunately, recent data presented by 
Stegall et al. (Stegall et al.,2010, as cited in Jordan, S, 2010)  supports this contention. These 
investigators treated ten patients who underwent desensitization with plasmapheresis + 
IVIG with eculizumab after transplantation. After nearly 12 months of follow-up for all 
patients, none developed AMR. Several protocol biopsies showed C4d deposits but no 
evidence of AMR. This finding is suggestive of incomplete complement activation, which is 
permissive for accommodation. This author says, that a combination of high-dose IVIG with 
eculizumab maybe act to modify elements of cellular immunity, humoral immunity, and 
complement effectors. Confirmation of these ideas awaits clinical trials. 
3.1.11 Receptor antagonists interleukin-2 (I1-2R): Basiliximab  
This anti-CD25 monoclonal antibody, one chimeric (basiliximab) are widely used in renal 
transplantation patients with low-moderate immunological risk during the induction phase. 
Usually, induction therapy with basiliximab is used in combination with calcineurin-
inhibitors, derivatives of mycophenolic acid and prednisone This antibody is directed 
against a chain of IL-2 receptor, whose expression on the cell surface requires activation of 
the T cell. Basiliximab is used in two doses of 20 mg each, for intravenous injection at time of 
transplantation and on the fourth day after transplantation, respectively. The first dose 
should be administered before reperfusion of the organ. Hypersensitivity reactions, 
including anaphylaxis, have been reported in isolation with the use of these antibodies, 
which, moreover, are considered safe and an adverse event profile similar to those reported 
with placebo.  
3.1.12 Therapeutic apheresis 
Plasmapheresis is a plasma exchange procedure to removal from blood plasma molecules 
with specific antigen recognition like antibodies or autoantibodies, molecules that alter the 
physical properties of plasma, immune complexes, toxic molecules and others. The 
therapeutic goal of plasma is to reduce circulating levels of these molecules to mitigate the 
underlying disease process. The vast majority of disorders successfully treated by 
plasmapheresis treatment involving the removal of IgG, as it has a longer half life and low 
rate of synthesis. Other factors removed as complement, coagulation proteins or 
inflammatory mediators contribute to a lesser extent the therapeutic benefit of 
plasmapheresis by its short half-life and high rate of synthesis.  
Therapeutic plasma exchange has been used successfully in the treatment of many 
hematological, neurological, renal, and metabolic disorders, rheumatic and acute humoral 
rejection.  This last is a condition that requires early diagnosis and intervention. Many 
groups have developed protocols for immunosuppression and immunomodulation that 
often include therapeutic plasma exchange.  
Plasmapheresis therapy is successfully used in the treatment or prevention of rejection in 
solid organ transplantation. Although the cellular immune response is responsible for 
mediating most of the rejections of allografts, acute humoral rejection of the transplanted 
organ refers to a severe dysfunction associated with the presence of antibodies directed 
against the donor organ. This type of rejection is generally resistant to immunosuppressive 
and immunomodulatory therapies, occurs more frequently in patients with preexisting 
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antibodies to the ABO system antigens or HLA expressed by the graft and is associated with 
a poor prognosis for graft survival. Numerous studies showed evidence of HLA antibodies 
decreased with plasmapheresis; in addition, patients with refractory acute rejection, the use 
of plasma exchange schemes and IVIG results in a better renal graft survival. The number of 
plasmapheresis sessions is greater the higher the antibody titer donor-specific. In addition, 
as soon as plasmapheresis stops, there is a rebound in the title antibody. Therefore, 
plasmapheresis is considered an additional technical assistance to other therapeutic 
procedures, particularly treatment with IVIG.  
Extracorporeal immunoadsorption is other technique for the elimination of pathogenic 
antibodies and circulating immune complexes. Immunoadsorption is capable to eliminate 
huge amounts of immunoglobulins from the patient's circulation with a minimum of side 
effects (associated with the substitution of fresh frozen plasma or albumin or removal of 
other plasmatic factors to above 50%).  
Most evidences about immunoadsorption are based on uncontrolled case series and 
individual observations. Indications for extracorporeal immunoadsorption are presently 
limited to HLA-pre-sensitised kidney recipients, rapidly progressive glomerulonephritis, 
haemolytic uraemic syndrome, life-threatening autoimmune diseases among others. 
Immunoadsorption devices can be subdivided into non-selective, semi-selective and highly 
selective adsorbers. In patients with acute vascular rejection after renal transplantation, 
immunoadsorption can be used to remove anti-HLA antibodies in combination with 
conventional anti-rejection therapy. It seems feasible to apply immunoadsorption instead of 
plasmapheresis for acute, vascular rejection although a controlled trial should demonstrate 
whether one or the other is more effective and associated with less adverse effects.  
Immunoadsorption could also be successfully used for the reduction of anti-HLA antibody 
titre before transplantation for obtaining a negative cross match in highly sensitised 
patients. A median of plasma processed during the pre-transplant immunoadsorption 
session could be high and may not be achieved with the use of plasmapheresis due to a high 
likelihood of adverse reactions attributable to the administration of fresh frozen plasma or 
albumin. By contrast to plasmapheresis, immunoadsorption allows the treatment of higher 
plasma volumes with a greater reduction of immunoglobulins (immunoadsorption is 
capable of removing >85% of IgG during one session). In the future, immunoadsorption 
may replace plasmapheresis in the treatment of some but not all diseases, however, the high 
costs associated with immunoadsorption therapy must be taken into account. (Schwenger,& 
Morath,C, 2010).   
3.1.13 Others agents in Phase I, II or III clinical trials 
ISA247 (voclosporine), a cyclosporine analogue, has the advantage of inducing less 
postransplantation diabetes and reduced nephrotoxicity (Phase III study). 
CP-690550, a specific inhibitor of the JAK3 protein kinase, has an effect comparable to 
tacrolimus on the acute rejection rate and kidney function. Orally is administered with 
basiliximab, mycophenolate and steroids. Initial results suggest that co-administration with 
mycophenolate involves excessive immunosuppression, with increased BK virus infection 
and cytomegalovirus. 
Belatacept, is a humanized antibody that blocks the costimulatory signal by binding to CD80 
and CD86 antigen presenting cells, thereby promoting anergy and apoptosis of T cells. Its 
efficacy is similar to that of cyclosporin A, but with a more favorable toxicity profile. The 
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need for intravenous injection and a slight increase in the development of 
lymphoproliferative disease in liver transplantation recipients with negative serology to 
Epstein-Barr virus could partially limit its use (Multiple Phase II and III trials). 
Alefacept and Efaluzimab are humanized antibodies that inhibit T-cell adhesion and are in 
Phase I and II clinical trials. 
3.2 Clinical evidences on desensitization therapy strategies in high immunological 
risk patients  
In this section, we review the most relevant publications related to therapies in high 
immunologic risk patients, making emphasis on aspects such as incidence of acute rejection, 
long-term allograft survival and function, mortality and others. Highly sensitized transplant 
recipients, regardless of the desensitization protocol used, are at increased risk for AMR. 
Both desensitization and AMR are managed with the similar therapeutic arsenal; however 
protocols are center-specific and there are no consensus guidelines. The two desensitization 
protocols more frequently used are high-dose IVIG or low-dose IVIG with either 
plasmapheresis or immunoadsorption. Additionally, some transplant centers may add 
intravenous steroids, rabbit antithymocyte globulin, or rituximab. For variant of AMR 
where over 30% of infiltrating cells are mature plasma cells, which do not express CD20, 
several transplant centers have utilized bortezomib instead of rituximab.  
Yuan XP et al (Yuan XP et al., 2010) evaluated the efficacy of plasmapheresis plus low-dose 
intravenous immunoglobulin in highly sensitized patients waiting for a deceased-donor 
renal transplant. In 25 patients (group 1), a positive T- and/or B-cell cytotoxicity crossmatch 
was rendered negative by plasmapheresis plus low-dose intravenous immunoglobulin 
treatment. During the same time, 32 highly sensitized patients (group 2), without 
desensitization, had a negative crossmatch and received deceased-donor renal transplants. 
Group 1 showed a numerically higher rate of acute rejection and antibody-mediated 
rejection, but the difference was not statistically significant. No differences in Kaplan-Meier 
graft survival were found between group 1 and group 2 after long-term follow-up. They 
conclude that desensitization with plasmapheresis, plus low-dose intravenous 
immunoglobulin enables successful deceased-donor renal transplant in highly sensitized 
patients with a positive crossmatch and achieve results similar to highly sensitized patients 
with negative crossmatch. Moreover, antibody-mediated rejection occurred predominantly 
in recipients with donor-specific antibodies of high titers. They used anti-thymocyte 
globulin for induction in both groups.  
Loupy A, (Loupy A et al., 2010), combined posttransplant prophylactic intravenous 
immunoglobulin, rituximab and plasmapheresis in kidney recipients with preformed 
donor-specific antibodies. All patients had a concomitant evaluation of glomerular filtration 
rate, protocol biopsies, and DSA mean intensity of fluorescence (MFI) at 3 month and 1 year 
posttransplant. The first strategy combined posttransplant quadritherapy and intravenous 
immunoglobulin (group 1, n=36) and the second added to the above protocol rituximab and 
plasmapheresis (group 2, n=18). Peak and day-0 class-I or II DSA max-MFI were similar in 
both groups. The rate of acute antibody-mediated rejection (AMR) was similar in both 
groups (about 19.6% vs. 16.6%, respectively). At 1 year posttransplant, group 2 was 
characterized significantly by lower score microcirculation inflammation lesions, a lower 
rate of transplant glomerulopathy and a lower rate of chronic AMR. The decline in DSA-
MFI from day 0 to 1 year was about 44% in group 1 compared with 80% in group 2 and the 
1-year glomerular filtration rate was about 43 vs. 54 ml/min/1.73 m2, respectively. The 
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study raises the possibility that a more prophylactic immunosuppressive strategy at day 0 
combining intravenous immunoglobulin/anti-CD20/plasmapheresis in high-risk 
population, is associated with significant differences in long-term function and chronic 
AMR rate, although similar rates of early acute clinical humoral rejection may be observed.  
Vo A, et al (Vo AA et al., 2010, 2008) used high-dose intravenous immune globulin (2 g/kg 
x2 doses) and rituximab (2 doses) for desensitization of highly HLA-sensitized patients 
awaiting kidney transplantation. All patients received intravenous ganciclovir while staying 
at the hospital and valganciclovir for 6 months as outpatients, with dose adjustments for 
renal function. Both fungal and bacterial infection prophylaxis, including Pneumocystis 
carinii, was performed in all patients according to standard clinical practice. From July 2006 
to February 2009, seventy-six treated patients (31 living donors, 45 deceased donors) were 
transplanted. For living donors (LD) and deceased donors (DD) recipients, significant 
reductions were seen in T-cell flow cytometry crossmatch from pretreatment to time of 
transplant. Patients received their kidney transplants when the complement-dependent 
cytotoxicity (CDC) T-cell crossmatch was negative at a 1:2 dilution of serum or the mean 
flow-channel shift in the T-cell flow-cytometric crossmatch was below 250. Time on wait list 
for DD recipients was reduced from a mean of 95 to 4.2 months after treatment; 37% 
experienced acute rejection but patient and graft survival up to 24 months was 95% and 
84%, respectively. The mean serum creatinine, at 12 and 24 months were about 1.5 and 1.3 
mg/dl, respectively. They concluded that IVIG and rituximab seems to offer significant 
benefits in reduction of anti-HLA antibodies allowing improved rates of transplantation for 
highly sensitized patients, especially those awaiting DD, with acceptable antibody-mediated 
rejection and survival rates at 24 months. All patients had reduced numbers of CD19+ cells 
after rituximab infusion. No patients developed neurologic symptoms suggestive of 
progressive multifocal leukoencephalopathy or required further hospitalization, and the 
rate of urinary tract infection was not greater than that among transplant recipients who 
were not highly sensitized. No other important infectious complications were noted.  
Although 13 of 16 patients who received a kidney transplant had a persisting positive 
crossmatch at the time of transplantation (below the threshold given above), no hyperacute 
rejection episodes were noted. The same group developed an in vitro test system to predict 
whether intravenous immune globulin might reduce PRA or crossmatch positivity in 
individual patients. For patients who did not respond well in this test system or who had high 
antibody titers before desensitization, intravenous immune globulin and rituximab were 
considered not to be sufficient alone, and the patients received in addition plasmapheresis. 
Vo AA, Jordan SC, et al (Vo AA; Jordan, SC. et al., 2008, 2009), analyzed the use of 
subcutaneous alemtuzumab induction therapy with intravenous immune globulin and 
rituximab in an uncontrolled study in 54 highly HLA-sensitized patients from 3/05 to 4/07. 
No patient developed acute injection-related reactions after alemtuzumab, however, bone 
marrow suppression was occasionally seen requiring reduction or elimination of 
mycophenolate mofetil approximately 1-2 months posttransplant. Patient and graft survival 
at 12 month was 98%/96%, respectively. Acute rejection episodes occurred in 35% with 20% 
being C4d+ acute rejection. Mean serum creatinine at 12 month was about 1.4 mg/dl. 
Infections occurred in eight patients (five with polyoma BK viremia, one CMV/PBK and 
two with CMV viremia). They concluded that induction therapy with alemtuzumab appears 
feasible and indeed promising, but awaits more definitive study. 
Scemla A et al (Scemla A et al., 2010), revised the incidence of infectious complications in 38 
highly sensitized renal transplant recipients treated by rituximab. They compared this 
population with 26 highly sensitized renal transplant recipients who received comparable 
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treatment but without rituximab. Mean posttransplant follow-up was 25.5±11.5 and 
34.6±16.4 months in the rituximab and control groups, respectively. A total of 84 severe 
infectious episodes occurred in 39 patients (rituximab 55.3% vs. controls 69.2%, ns). Two 
patients died in each group. Three of these four deaths were related to infectious 
complications. Specifically, rituximab was not associated with an increased risk of infection. 
Kamar N et al (Kamar N et al., 2010), revised the occurrence of infectious disease and its 
outcome after rituximab therapy (375 mg/m2, 2-8 courses) in 77 kidney-transplant patients 
between April 2004 and August 2008. Their results were compared with a control group 
(n=902) who had received no rituximab. After a median follow-up of 16.5 months for 
rituximab patients and 60.9 months for control patients, the incidence of infectious disease 
was 45.45% and 53.9% (ns), respectively. The incidence of bacterial infection was similar 
between the two groups, whereas the viral-infection rate was significantly lower, and the 
rate of fungal infection was significantly higher in the rituximab group. Nine out of 77 
patients died after rituximab therapy, of which seven deaths were related to an infectious 
disease, compared to 1.55% in the controls (p=0.0007). They concluded that in the whole 
population, the independent predictive factors for infection-induced death were the 
combined use of rituximab and antithymocyte-globulin given for induction or anti-rejection 
therapy, recipient age, and bacterial and fungal infections.  
Flechner SM et al (Flechner SM et al., 2010), revised the role of proteasome inhibition with 
bortezomib in the treatment of antibody-mediated rejection in 20 patients. AMR was 
diagnosed about 19.8 months posttransplant. De novo class I DSA was detected in 55% and 
class II DSA in 90% recipients. Patients received intravenous corticosteroids followed by a 2-
week cycle on days 1, 4, 8 and 11 of plasmapheresis and 1.3 mg/m² bortezomib; then 0.5 
mg/kg intravenous immunoglobulin four times. Their results were a significantly 
decrement in peak-nadir dominant DSA. Patient survival was 100%, and graft survival 85% 
with a mean follow-up of 9.8 months. The treatment was generally well tolerated but caused 
fatigue, gastrointestinal complaints, fluid retention, and thrombocytopenia in a number of 
patients. The last follow-up estimated glomerular filtration rate was 41.9±16.8 ml/min, 
however, only 25% returned to their baseline renal function. They concluded that the 
bortezomib-containing regimen demonstrated activity in AMR but seems to be most 
effective before the onset of significant renal dysfunction or proteinuria and the use of 
bortezomib to treat AMR should be evaluated in controlled trials using dosing strategies 
that include longer courses or retreatment schedules.  
Something similar was found by Raghavan R et al (Raghavan R et al, 2010), this author 
revised the use of bortezomib in kidney transplantation and said that the use of this 
biological agent in the field of transplantation may seem to show promise in the realm of 
transplant recipients desensitization and treatment of AMR, and will be defined better as 
more clinical data and trials become available. 
Lonze BE et al (Lonze BE et al., 2010) review a 43-year-old patient with end-stage renal 
disease and 100% panel reactive antibody who was treated with desensitization protocol 
using two cycles of bortezomib undertaken after anti-CD20 and intravenous 
inmunoglobulins. A flow-positive, cytotoxic-negative cross-match live-donor kidney at the 
end of an eight-way multi-institution domino chain became available. The patient received 
three pretransplant plasmapheresis treatments. Intraoperatively, the superior mesenteric 
vein was the only identifiable patent target for venous drainage. Eculizumab was 
administered postoperatively in the setting of antibody-mediated rejection and an inability 
to perform additional plasmapheresis. Creatinine remains normal at 6 months 
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posttransplant and flow cross-match remained negative. In this report, they described the 
combined use of new agents (bortezomib and eculizumab) and modalities (nontraditional 
vascular access, splanchnic drainage of graft and domino paired donation) in a patient who 
would have died without transplantation. 
Wahrmann M et al, (Wahrmann M et al., 2010), analized two sensitized hemodialysis 
patients that were selected to receive two subsequent bortezomib cycles (1.3 mg/m2 on days 
1, 4, 8, and 11). Dexamethasone was added to the second cycle to enhance treatment 
efficiency. During a half-year follow-up period, cytotoxic panel reactive antibody decreased 
from 87% to 80% (patient 1) and 37% to 13% (patient 2). Patient 1 showed a 40% reduction in 
binding intensities of identified Luminex HLA single antigen reactivities and, in parallel, 
slight reductions in ABO blood group antibody and total immunoglobulin levels. In patient 
2, bortezomib did not affect circulating antibody levels in a meaningful way. Both patients 
showed a more than 50% reduction in the levels of anti-HLA antibody-triggered C4d 
deposition to Luminex beads. They concluded that, without additional immunosuppressive 
measures, bortezomib has modest effects on circulating antibodies against HLA or blood 
group antigens. Hovewer, the reduced levels of antibody-triggered complement fixation, 
imply potential clinical relevance of proteasome inhibition for recipient desensitization. 
Sberro-Soussan R (Sberro-Soussan R, et al., 2010), evaluated the in vivo efficacy of one cycle 
of bortezomib (1.3 mg/m2 x 4 doses), used as the sole desensitization therapy, in four renal 
transplant recipients experiencing subacute antibody-mediated rejection with persisting 
DSA (>2000 Mean Fluorescence Intensity, MFI). Bortezomib treatment did not significantly 
decrease DSA MFI within the 150-day posttreatment period in any patient. In addition, 
antivirus (HBV, VZV and HSV) antibody levels remained stable following treatment 
suggesting a lack of efficacy on long-lived plasma cells. They concluded that one cycle of 
bortezomib alone does not decrease DSA levels in sensitized kidney transplant recipients in 
the time period studied and need to evaluate this new desensitization agent properly in 
prospective, randomized and well-controlled studies.  
Locke JE et al, (Locke JE et al., 2009) present a single case in which eculizumab was used 
combined with plasmapheresis e inmunoglobulins to salvage a kidney undergoing severe 
AMR. They showed a marked decrease in C5b-C9 (MAC) complex deposition in the kidney 
after the administration of eculizumab.  
Stegall et al. recently reported on their results obtained in a first series of patients in whom 
the use of eculizumab was tested for the prevention of AMR in crossmatch-positive kidney 
transplantation. Sixteen crossmatch-positive kidney transplantations realized under the 
usage of eculizumab were compared to a historical control group of 51 transplantations 
where desensitization had been performed without eculizumab. Acute humoral rejection 
was found in only 6% of patients desensitized with eculizumab as compared to a 40% rate in 
the historical control group. However, 4 of 16 patients in the eculizumab group with 
persistent levels of high DSA after transplantation showed signs of chronic allograft injury, 
including endothelial cell activation and transplant glomerulopathy (Stegall,2010, as cited in 
C. Siisal & Morath C, 2011). 
Thielke et al. reported that a negative crossmatch was successfully achieved in 51 of 57 
positive-crossmatch patients treated with antithymocyte and anti-CD20 antibody induction 
therapy in addition to plasma exchange and low-dose intravenous immunoglobulin. The 
rate of allograft survival was 93% at 1 year and 81% at 2 years.  
Glotz et al (Glotz et al., 2002) reported 15 patients with either a panel reactive antibody 
(PRA) of >50 percent or with a positive crossmatch to their potential living donor who were 
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given 2 g/kg of IVIG monthly for three months. Thirteen of the 15 showed evidence of 
desensitization (reduction of PRA by at least 50 percent or a repeat negative crossmatch to 
the living donor) and underwent renal transplantation. The mean decrease in PRA for 
recipients was 80 percent and a post-IVIG administration NIH cytotoxicity crossmatch was 
negative prior to transplantation. The IVIG was repeated at the same dose on post-
transplant day zero and one. Thymoglobulin was used for induction and maintenance 
immunosuppression consisted of mycophenolate, corticosteroids and tacrolimus. The IVIG 
was again repeated at post-transplant day 20 or 21 and 40 or 41. One graft was lost 
secondary to thrombosis and one graft was lost secondary to rejection. No other episodes of 
rejection were reported in the remaining allografts during follow-up of over one year.  
Kaposztas et al. reported 2-year outcomes in their recent retrospective study looking at 54 
patients treated for AMR. Group A had 26 patients who underwent treatment with 
plasmapheresis and rituximab, and group B had 28 patients who received plasmapheresis 
without rituximab. Patients who had low serum IgG levels also received IVIG. Two-year 
graft survival was significantly better in the group that received rituximab (90% vs 60%), 
with the difference attributed to rituximab. A trend toward improved graft survival was 
also seen in those who received IVIG. This retrospective study has one of the largest cohorts 
reported to date and supports the use of rituximab for treating AMR, with good short-term 
allograft survival; however, many patient variables were not consistent between the groups 
(Kaposztas et al, 2009, as cited in Jordan, S, 2010). 
Gloor et al, (Gloor et al., 2003) described 14 patients with a positive cytotoxicity crossmatch to 
a potential living donor. Patients underwent plasmapheresis on days four, three, and one 
pretransplant, on the day of transplantation, and on day one and three post-transplantation. 
Intravenous immunoglobulin 100 mg/kg was administered after each plasmapheresis session. 
Rituximab at a dose of 375 mg/m2 was given on post-transplant day four. Splenectomy was 
performed at the time of transplantation in those with an intact spleen (two had previously 
been splenectomized). Thymoglobulin was used for induction and tacrolimus, mycophenolate 
and corticosteroids were used for maintenance therapy. Patient survival at a mean follow-up 
of 15 months was 86 percent. Histologic evidence of AMR occurred in 43 percent. The risk of 
AMR was related to the baseline anti-HLA antibody titer. All four subclinical episodes 
responded to treatment and follow-up protocol biopsies showed no histologic evidence of 
rejection. Both episodes of rejection defined as clinically significant AMR demonstrated 
evidence of chronic allograft nephropathy on subsequent biopsies. 
Stegall et al (Stegall et al, 2006, as cited in C. Siisal & Morath C, 2011) deigned one study to 
compare high dose IVIG (13 patients) with plasmapheresis/low dose IVIG protocols (32 
patients) in renal transplant recipients with high DSA levels. Plasmapheresis plus low dose 
intravenous inmunoglobulins (IVIG) received also anti-CD20 antibody (32 patients), and 19 of 
the 32 patients in this group also underwent splenectomy; post-transplant plasmapheresis and 
low dose IVIG were continued on post-surgery days one to three for a total of two to three 
sessions. High single dose IVIG (13 patients), which is the high dose IVIG group. 
Plasmapheresis plus low dose IVIG plus anti-CD20 antibody plus pretransplant 
Thymoglobulin combined with post-transplant DSA monitoring (16 patients), was the 
plasmapheresis/monitoring group. Achieving a negative crossmatch was significantly more 
likely with both plasmapheresis protocols versus high dose IVIG (84, 88, and 38 percent 
respectively). Significantly lower humoral rejection rates were also reported with the 
plasmapheresis protocols (37, 29, and 80 percent, respectively), although none of the patients 
in the high single dose IVIG group received rituximab or post-transplant administration of 
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IVIG. Patients with low baseline antibody titers responding to high dose IVIG may do equally 
as well with further optimization of therapy. However, whether or not the administration of 
rituximab or the routine post-transplant administration of IVIG would be of benefit in 
reducing the incidence of acute rejection in a high dose IVIG protocol is unclear at this time as 
this study not included randomization and only participated a low numbers of patients.  
4. Remarks and conclusions 
The main goal of monitoring circulating antibodies is to measure PRA and identify specific 
antibodies in order to evaluate the patient’s immunological risk and interpret a crossmatch. 
The introduction of HLA antibody characterization based on interactions between recipient 
serum and purified HLA antigens bound to solid-phase substrates has improved detection 
and quantification of donor-specific antibodies (DSAs).  
Currently, few kidney transplant options exist for hypersensitive patients on the waiting list if 
they do not undergo previously to desensitising treatments or strong induction therapy. In this 
respect, high doses of intravenous immunoglobulins may reduce the level of circulating 
antibodies, but, many patients only respond partially, and the efficacy varies among patients. 
Plasmapheresis can decrease circulating antibodies, but there is normally a significant increase 
in their titre levels once the sessions have been completed. Therefore, this technique is now 
considered a complement to the use of immunoglobulins for decreasing antibody levels. 
Likewise, rituximab has also been shown to have a beneficial effect when combined with 
immunoglobulins and plasmapheresis to reduce anti-HLA antibodies rate and to treat 
antibody-mediated rejection. On the other hand, newer interventions aimed at the prevention 
of DSA-mediated allograft injury using complement blockade, or the inhibition of DSA 
synthesis using proteasome inhibitor-mediated plasma cell depletion are promising.  
In any case, the best therapeutic strategy may be of combining these drugs, particularly 
when there is early detection of acute antibody-mediated rejection through histological or 
serological techniques. Whether long-term beneficial outcomes are achived with these drugs 
without life-threatening side-effects, remains to be elucidate.  
According to our previous results, we tentatively propose the following desensitization and 
induction protocol:  
Recipients with positive cytotoxicity crossmatch or retransplantation recipients with positive 
cytometry crossmatch and negative cytotoxicity crossmatch are potential candidates for pre-
transplant desensitisation. For first transplant recipients with positive cytometry crossmatch 
but with negative cytotoxicity crossmatch, desensitisation may not be necessary. For patients 
who are only positive for virtual lymphocyte crosssmatch, with negative cytotoxicity and 
cytometry crossmatches, there are currently insufficient data that support the appropriateness 
of desensitisation. Patients on the waiting list more than 12 months and at least three studies 
quarterly permanently with PRA> 50-75% polyspecific, multiple previous positive crossmatch, 
and multiple HLA-antigens positive reactivity that makes transplantation highly unlikely, if 
they have absence of IgA deficiency and antibodies antiIgA, they could receive high dose of 
immunoglobulins, plus plasmapheresis and one or two doses of rituximab.  
Requirements for performing kidney transplantation in these patients would be:  
a. Pre-transplant negative cytotoxicity crossmatch, and  
b. Negative virtual crossmatch test prior to the kidney transplant, i.e., abscense of all class 
I or II HLA antigens in the donor that have produced an alloresponse in the recipient at 
any time.  
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c. Induction therapy with thymoglobulin tacrolimus, mycophenolate, 
methylprednisolone.  
d. Desensitisation treatment would consist in rituximab, various plasmapheresis sessions 
with IV immunoglobulin infusion following each session.  
e. Monitorization of CD19+/CD20+ lymphocyte populations and checking for any 
appearance of opportunistic infections using a PCR assay for CMV, Epstein-Barr viral 
serology, B-19 parvovirus and polyomavirus BK are necessary. 
f. Cytomegalovirus infection prophylaxis with gancyclovir/valgancyclovir 6 months, 
pneumocistis jirovecii prophylaxis with trimethoprim sulfamethoxazole and fungal 
infection prophylaxis with nystatin or oral fluconazole must be considered.  
g. Monitoring PRA title every 15 days the first 3 months and then monthly during first year 
and before or after any deterioration of renal function. A rising DSA titter may suggests 
the need for intensification of therapy with potential modification of maintenance 
immunosuppression or initiating intensive therapy using IVIG and/or plasmapheresis.  
h. Monitoring of neurological symptoms: progressive multifocal leukoencephalopathy, 
reactivation of polyoma JC virus also is very important.  
i. In the case of immunoligal-mediated renal dysfunction, it is important perform a graft 
biopsy and C4d staining. Treatment for apparent AMR is essentially by combining 
metilprednisolone, plasmapheresis (or immunoadsorption) and IVIG, with a duration 
that will be dependent upon an improvement in renal function, decrease in the titter of 
DSA or improvement of biopsy findings. If there is no good response to treatment, 
individual assess whether repeated rescue therapies, such as rituximab or eculizumab. 
In the case of appearance of plasma cells in the renal graft biopsy, it should be assessed 
individually using bortezomib as salvage therapy. Subclinical rejection (as defined by 
positive C4d staining associated with histologic evidence of antibody mediated 
rejection) on protocol biopsies may be associated with future AMR or subsequent 
evidence of chronic allograft injury. Whether or not treatment of subclinical rejection in 
this setting has a benefit on long-term graft survival is unknown, however, given the 
high risk of acute rejection, most physicians would favor restarting 
plasmapheresis/IVIG or other treatment. 
j. An additional critical issue is antibody development against allogeneic antigen systems 
on graft other than HLA that are not necessarily detected in routine antibody testing, 
like anti-major histocompatibility complex class I related A (anti-MICA), antiendothelial 
antibodies, antibody binding to angiotensin type-1 receptor and others. These 
antibodies have found a strong association with antibody-mediated rejection in 
recipients whose sera did not contain antibody to donor HLA, indicating that 
antibodies directed against non-HLA antigens also have a certain impact. These issues 
are not reasons for this chapter and may be addressed in future. More studies are 
required in this field to determine the frequency and magnitude of damage caused by 
non-HLA immunity. 
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